Kymera Therapeutics reported revenue of $65.00M and net income of -$64.17M for the quarter ended Jun 2026, up 466.4% year over year. This income statement covers 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||||||||||||||
| Revenue | 20.34M | 15.28M | 9.62M | 11.51M | 9.55M | 16.14M | 9.47M | 16.51M | 4.73M | 47.88M | 10.29M | 25.65M | 3.74M | 7.39M | 22.10M | 11.48M | 2.76M | 2.87M | 34.37M | 65.00M | ||||||||
| Operating items | ||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 38.31M | 37.53M | 35.94M | 41.29M | 43.88M | 43.13M | 42.23M | 45.77M | 48.12M | 52.97M | 48.82M | 59.20M | 60.41M | 71.82M | 80.25M | 78.39M | 74.09M | 83.83M | 98.16M | 119.48M | ||||||||
| Selling, General & AdministrativeSG&A | 10.67M | 11.74M | 10.61M | 11.03M | 10.56M | 11.64M | 12.56M | 14.13M | 14.12M | 14.23M | 14.37M | 17.37M | 15.46M | 16.33M | 16.27M | 17.64M | 17.34M | 16.93M | 20.36M | 21.13M | ||||||||
| Other Operating ExpensesOther Opex | 4.92M | 3.85M | ||||||||||||||||||||||||||
| Operating ExpensesOpex | 48.97M | 49.27M | 46.55M | 52.32M | 54.43M | 54.77M | 54.79M | 59.90M | 62.24M | 67.20M | 68.12M | 76.58M | 75.86M | 88.15M | 96.53M | 96.03M | 95.28M | 100.77M | 118.52M | 140.61M | ||||||||
| Operating IncomeOp. Inc | -28.64M | -33.99M | -36.93M | -40.81M | -44.88M | -38.63M | -45.33M | -43.38M | -57.51M | -19.31M | -57.83M | -50.92M | -72.12M | -80.75M | -74.43M | -84.56M | -92.52M | -97.90M | -84.15M | -75.61M | ||||||||
| EBIT | -28.64M | -33.99M | -36.93M | -40.81M | -44.88M | -38.63M | -45.33M | -43.38M | -57.51M | -19.31M | -57.83M | -50.92M | -72.12M | -80.75M | -74.43M | -84.56M | -92.52M | -97.90M | -84.15M | -75.61M | ||||||||
| Non-operating items | ||||||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.07M | 0.05M | 0.04M | 0.04M | 0.04M | 0.06M | 0.06M | 0.05M | 0.04M | 0.05M | 0.07M | 0.06M | 0.06M | 0.06M | 0.07M | 0.11M | 0.10M | 0.09M | 0.06M | 0.08M | ||||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.12M | 0.14M | 0.29M | 0.59M | 1.92M | 3.82M | 4.45M | 4.63M | 4.68M | 5.00M | 9.34M | 8.92M | 9.70M | 10.06M | 8.92M | 8.05M | 10.44M | 11.01M | 14.98M | 14.48M | ||||||||
| Net income details | ||||||||||||||||||||||||||||
| EBT | -28.71M | -34.05M | -36.97M | -40.85M | -44.92M | -38.69M | -45.38M | -43.43M | -57.55M | -19.36M | -57.90M | -50.99M | -72.18M | -80.81M | -74.50M | -84.67M | -92.62M | -97.99M | -84.22M | -75.69M | ||||||||
| Profit After TaxPAT | -28.58M | -34.43M | -36.68M | -41.02M | -44.93M | -33.90M | -40.93M | -39.40M | -52.87M | -14.37M | -49.78M | -42.38M | -62.49M | -71.69M | -65.58M | -76.61M | -82.17M | -86.98M | -75.23M | -64.17M | ||||||||
| Income from Continuing OperationsIncome (Continuing) | -28.71M | -34.05M | -36.97M | -40.85M | -44.92M | -38.69M | -45.38M | -43.43M | -57.55M | -19.36M | -57.90M | -50.99M | -72.18M | -80.81M | -74.50M | -84.67M | -92.62M | -97.99M | -84.22M | -75.69M | ||||||||
| Consolidated Net IncomeConsol Net Inc. | -28.71M | -34.05M | -36.97M | -40.85M | -44.92M | -38.69M | -45.38M | -43.43M | -57.55M | -19.36M | -57.90M | -50.99M | -72.18M | -80.81M | -74.50M | -84.67M | -92.62M | -97.99M | -84.22M | -75.69M | ||||||||
| Income towards Parent CompanyParent Net Inc | -28.71M | -34.05M | -36.97M | -40.85M | -44.92M | -38.69M | -45.38M | -43.43M | -57.55M | -19.36M | -57.90M | -50.99M | -72.18M | -80.81M | -74.50M | -84.67M | -92.62M | -97.99M | -84.22M | -75.69M | ||||||||
| Preferred Dividend PaymentsPref Dividends | ||||||||||||||||||||||||||||
| Net Income towards Common StockholdersNet Income | -28.71M | -34.05M | -36.97M | -40.26M | -43.00M | -34.87M | -40.93M | -38.80M | -52.87M | -14.37M | -48.56M | -42.06M | -62.49M | -70.75M | -65.58M | -76.61M | -82.17M | -86.98M | -69.23M | -61.21M | ||||||||
| Additional items | ||||||||||||||||||||||||||||
| EPS (Basic) | -0.57 | -0.71 | -0.72 | -0.78 | -0.79 | -0.65 | -0.70 | -0.67 | -0.90 | -0.25 | -0.69 | -0.58 | -0.82 | -0.94 | -0.82 | -0.95 | -0.94 | -1.03 | -0.71 | -0.62 | ||||||||
| EPS (Diluted) | -0.57 | -0.71 | -0.72 | -0.78 | -0.79 | -0.65 | -0.70 | -0.67 | -0.90 | -0.25 | -0.69 | -0.58 | -0.82 | -0.94 | -0.82 | -0.95 | -0.94 | -1.03 | -0.71 | -0.62 | ||||||||
| Shares Outstanding | 50.71M | 47.99M | 51.65M | 51.77M | 54.54M | 53.93M | 58.19M | 58.33M | 58.42M | 58.37M | 70.77M | 73.06M | 76.13M | 75.04M | 80.15M | 80.45M | 87.30M | 84.49M | 97.53M | 98.18M | ||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 50.71M | 47.99M | 51.65M | 51.77M | 54.54M | 53.93M | 58.19M | 58.33M | 58.42M | 58.37M | 70.77M | 73.06M | 76.13M | 75.04M | 80.15M | 80.45M | 87.30M | 84.49M | 97.53M | 98.18M | ||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 51.26M | 51.54M | 51.69M | 51.85M | 54.75M | 55.04M | 55.28M | 55.39M | 55.45M | 55.59M | 61.35M | 61.57M | 64.75M | 64.89M | 65.11M | 70.56M | 71.74M | 81.32M | 82.18M | 82.79M | ||||||||
| EBITDA | -28.64M | -33.99M | -36.93M | -40.81M | -44.88M | -38.63M | -45.33M | -43.38M | -57.51M | -19.31M | -57.83M | -50.92M | -72.12M | -80.75M | -74.43M | -84.56M | -92.52M | -97.90M | -84.15M | -75.61M | ||||||||
| Interest ExpensesInt Expense | 0.07M | 0.05M | 0.04M | 0.04M | 0.04M | 0.06M | 0.06M | 0.05M | 0.04M | 0.05M | 0.07M | 0.06M | 0.06M | 0.06M | 0.07M | 0.11M | 0.10M | 0.09M | 0.06M | 0.08M |